These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37132629)

  • 1. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
    Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
    Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
    Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
    JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
    Uson PLS; Riegert-Johnson D; Boardman L; Kisiel J; Mountjoy L; Patel N; Lizaola-Mayo B; Borad MJ; Ahn D; Sonbol MB; Jones J; Leighton JA; Gurudu S; Singh H; Klint M; Kunze KL; Golafshar MA; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab TS; Jewel Samadder N
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e508-e528. PubMed ID: 33857637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study.
    Uson Junior PL; Kunze KL; Golafshar MA; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Barrus K; Mountjoy L; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T; Samadder NJ
    Cancer Prev Res (Phila); 2022 Feb; 15(2):121-128. PubMed ID: 34782326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study.
    Uson PLS; Kunze KL; Golafshar MA; Botrus G; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Kahn A; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T; Samadder NJ
    Dig Dis Sci; 2022 Nov; 67(11):5107-5115. PubMed ID: 35122589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program.
    Jones JC; Golafshar MA; Coston TW; Rao R; Wysokinska E; Johnson E; Esplin ED; Nussbaum RL; Heald B; Klint M; Barrus K; Uson PL; Nguyen CC; Colon-Otero G; Bekaii-Saab TS; Dronca R; Kunze KL; Samadder NJ
    Cureus; 2023 Apr; 15(4):e37428. PubMed ID: 37181954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.
    Choudry MM; Durant AM; Edmonds VS; Warren CJ; Kunze KL; Golafshar MA; Nielsen SM; Esplin ED; Andrews JR; Samadder NJ; Tyson MD
    J Urol; 2024 Jun; ():101097JU0000000000004089. PubMed ID: 38860938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
    Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
    JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
    Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
    JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
    Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
    Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H
    Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
    Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
    Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
    Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
    JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
    Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
    Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
    Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline Pathogenic Variants in Squamous Cell Carcinoma of the Head and Neck.
    Drbohlavová T; Argalácsová S; Soukupová J; Vočka M
    Folia Biol (Praha); 2023; 69(4):107-115. PubMed ID: 38410968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
    Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
    JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
    Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED
    Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
    Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
    Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.